What is the Purpose of this Study?
The purpose of this study is to look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill. We want to test the use of a drug called bromocriptine for women who have a condition called "Peripartum cardiomyopathy" or PPCM. PPCM means you have a weak heart after giving birth. The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill. Bromocriptine is approved by the United States Food and Drug Administration (FDA) to treat irregular periods and other symptoms that result from having high blood levels of a substance called prolactin. It is not approved for use in usual care to treat PPCM.
Eligibility
- Recently diagnosed with Peripartum Cardiomyopathy (heart muscle weakness during and following pregnancy)
- Post-delivery and within the first 5 months post-partum.
- Clinical assessment of an LVEF < or = 0.40
- Age > 18
- Subject agrees not to breastfeed (there is an observational cohort for those who choose to breastfeed)
Where can I participate?
Cedars Sinai Medical Center
More about this Clinical Trial
What is the full name of this clinical trial?
Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy